Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects at least 18 years of age~* Constipated, defined by the following adapted ROME II definition:~A. Fewer than 3 spontaneous defecations per week and at least one of the following symptoms for at least 12 weeks (which need not be consecutive) in the preceding 12 months:~1. Straining during \> 25% of defecations~2. Lumpy or hard stools in \> 25% of defecations~3. Sensation of incomplete evacuation for \> 25% of defecations~B. Loose stools are rarely present without the use of laxatives~C. There are insufficient criteria for IBS - loose (mushy) or watery stool in the absence of laxative use for more than 25% of bowel movements~Criteria A, B and C must be fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis.~* Otherwise in good health, as determined by physical exam and medical history~* If female, and of child-bearing potential, is using an acceptable form of birth control~* Negative urine pregnancy test at screening, if applicable~* In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study~Exclusion Criteria:~* Subjects with known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, toxic megacolon~* Subjects who have had major surgery 30 days before Visit 1; appendectomy or cholecystectomy 60 days before Visit 1; abdominal, pelvic, or retroperitoneal surgery 6 months before Visit 1; bariatric surgery or surgery to remove a segment of the GI tract at any time before Visit 1~* Subjects with hypothyroidism that is being treated and for which the dose of thyroid hormone has not been stable for at least 6 weeks at the time of Visit 1~* Subjects taking laxatives, enemas or prokinetic agents that refuse to discontinue these treatments from Visit 1 until after completion of Visit 5~* Subjects who are pregnant or lactating, or intend to become pregnant during the study~* Subjects of childbearing potential who refuse a pregnancy test~* Subjects who are allergic to any study medication component~* Subjects taking narcotic analgesics or other medications known to cause constipation~* Subjects with clinically significant cardiac abnormalities identified at the Visit 1 ECG~* Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures~* Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days~* Subjects with an active history of drug or alcohol abuse~* Subjects have been hospitalized for a psychiatric condition or have made a suicide attempt during the 2 years before Visit 1~* Subjects who withdraw consent at any time prior to completion of Visit 1 procedures~* Subjects with known or suspected moderate to severe hepatic insufficiency (Child Pugh Classes B and C)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BLI400 Laxative (Type: EXPERIMENTAL): 21 gm BLI400 powder
- Lubiprostone (Type: ACTIVE_COMPARATOR): 24 mcg capsule bid

Based on this trial design, predict the completion outcome and termination type (if applicable).